JASON FLASSING: Open Payments
NPI 1912145970 · GREER, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$609 in 37 payments from 8 companies in 2025. Trend: 2023 $10,760 · 2024 $1,529 · 2025 $609
Food & beverage: $609
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $190 |
| Axsome Therapeutics, Inc. | 8 | $108 |
| ABBVIE INC. | 5 | $82 |
| Vanda Pharmaceuticals Inc. | 4 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| IDORSIA PHARMACEUTICALS US INC | 2 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
Products named: TRINTELLIX, VRAYLAR, Sunosi, HETLIOZ, REXULTI, Quviviq, CAPLYTA, Auvelity.
Industry payments across SC — which companies pay providers there.
